Blood pressure and cardiorenal responses to antihypertensive therapy in obese women

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 52, Issue 1, 2008, Pages 65-75

  Rosa, Eduardo Cantoni ^a,b   Zanella, Maria Tereza ^a   Kohlmann, Nárcia Elisa Bellucci ^a   Ferreira, Sandra Roberta Gouveia ^a   Plavnik, Frida Liane ^a   Ribeiro, Artur Beltrame ^a   Kohlmann Jr , Osvaldo ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Albuminuria; Antihypertensive therapy; Body fat distribution; Echocardiography; Hypertension; Obesity

Indexed keywords

EID: 41149162763     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302008000100010     Document Type: Article

References (52)

1. Kannel WB, Cupples LA, Ramaswami R, Stokes III, Kreger BE, Higgins M. Regional obesity and risk of cardiovascular disease: the Framingham Study. J Clin Epidemiol. 1991; 44:183-90.
2. Mark AL, Correia M, Morgan DA, Shaffer RA, Haynes WG. State-of-the-art-lecture: obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension. 1999;33:537-41.
3. Carneiro G, Faria AN, Ribeiro Filho FF, Guimarães A, Ferreira SR, Zanella MT. Influence of body fat distribution on the prevalence of arterial hypertension and other cardiovascular risk factors in obese patients. Rev Assoc Med Bras. 2003; 49:306-11.
4. Scaglione R, Ganguzza A, Corao J, Central obesity and hypertension: pathophysiologic role of renal haemodynamics and function. Int J Obes. 1995; 19:403-9.
5. Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor and leptin expression. Obes Res. 2003; 11:525-31.
6. Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol. 2004; 93:40-4.
7. Liese AD, Hense HW, Doring A, Stieber J, Keil U. Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg Survey 1994/95. J Hum Hypertens. 2001; 15:799-804.
8. Rosa EC, Zanella MT, Ribeiro AB, Kohlmann JO. Visceral obesity, hypertension and cardio-renal risk: a review, Arq Bras Endocrinol Metabol. 2005; 49:196-204.
9. Ribeiro Filho FF, Rosa EC, Faria A, Lerario DG, Ferreira SR, Kohlmann O, et al. Obesidade, hipertensão arterial e suas influências sobre a massa e função do ventrículo esquerdo. Arq Bras Endocrinol Metab. 2000; 44:64-71.
10. Masuo K, Mikani H, Ogihara T, Tuck ML. Weight reduction and pharmacologic treatment in obese hypertensives, Am J Hypertens. 2001; 14:530-8.
11. MacMahon SW, Wilcken DEL, Macdonald GJ. The effect of weight eduction on left ventricular mass: a randomized controlled trial in young, overweight hypertensive patients. N Engl J Med. 1986; 314:334-9.
12. Himeno E, Nishino K, Nakashima Y, Kuroiwa A, lkeda M. Weight reduction regresses left ventricular mass regardless of blood pressure level in obese subjects, Am Heart J, 1996; 131:313-9.
13. Sharma AM, Pischon T, Engeli S, Scholze J. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens. 2001; 19:667-74.
14. Aucott L, Poobalan A, Smith WC, Effects of weight loss in overweight/ obese individuals and long-term hypertension outcomes: a systematic review, Hypertension. 2005;45:1035-41.
15. Bramlage P, Pittrow D, Wittchen HU. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004; 17:904-10.
16. Zanella MT, Bapista M, Costa CH, Kohlmann NE, Kohlmann JO, Ribeiro AB. Comparative effects of captopril and chlortalidone on glucose tolerance and insulin levels in essential hypertensives. Arq Bras Cardiol. 1996; 67:47-52.
17. Reisin E, Weir MR, Fakner B, Hutchinson HG, Anzalone DA, Tuck ML. Treatment in Obese Patients with Hypertension (TROPHY) Study Group. Hypertension, 1997; 30(part1):140-5.
18. Jordan J, Engeli S, Boschmann M, Hemodinamic and metabolic responses to valsartan and atenolol in obese hypertensive patients, J Hypertens. 2005; 23:2313-8.
19. Grassi G, Seravalle G, Dell'Oro R. Comparative effects of candersartan and hydrochlortiazide on blood pressure, insulin sensitivity and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens. 2003; 21:1761-9.
20. Sugimoto K, Qi NR, Kazdova L. Telmisartan but not valsartan Increases caloric expenditure and protects against weight gain and hepatic steatosis, Hypertension. 2006; 47:1003-9.
21. Desprès J-P, Lemieux I, Prud'homme D, Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001; 322:716-20.
22. Cadaval RAM, Plavnik FL, Kohlmann NE, Kohlmann JO, Ribeiro AB, Zanella MT. Open comparative study of the effects of amlodipine and propanolol on insulin sensitivity in hypertensive patients with android obesity. Eur J Clin Res. 1996; 8:289-98.
23. Faria AN, Ribeiro Filho FF, Kohlmann NE, Ferreira SR, Zanella MT. Effect of sibutramine on abdominal fat mass, insulin tance and blood pressure in obese hypertensive patients. Diabetes Obes Metab. 2005; 7:246-53.
24. van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. Int J Obes. 1993; 17:187-96.
25. Lapidus L, Bengtsson C, Larsson B. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow-up of participants in the population study of women in Gotthenburg, Sweden. BMJ. 1984; 289:1257-61.
26. Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J. 2005; 149:54-60.
27. Yusuf S, Hawken S, Ôunpuu S, Bautista L, Franzosi MG, Commerford P et al, on behalf the INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case - control study. Lancet. 2005; 366:1640-9.
28. Snijder MB, Zi m met PZ, Visser M. Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. Int J Obes Relat Metab Disord. 2004; 28:402-9.
29. Després JP, Prud'homme D, Pouliot MC, Tremblay A, Bouchard C. Estimation of deep abdominal adipose-tissue accumulation from simple anthropometric measurements in men. Am J Clin Nutr. 1991; 54:471-7.
30. Vanhala MJ, Pitkajarvi TK, Kumpusalo EA, Takala JK. Obesity type and clustering of insulin resistance-associated cardiovascular risk factors in middle-aged men and women. Int J Obes. 1998; 22:369-74.
31. Rexrode KM, Carey VJ, Hepnekens CH, Walters FE, Colditz GA, Stamper MJ, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998; 280:1843-8.
32. Kortelainen ML, Särkioja T. Coronary atherosclerosis and myocardial hypertrophy in relation to body fat distribution in healthy women: an autopsy study on 33 violent deaths. Int J Obes. 1997; 21:43-9.
33. Devereux RB, Lutas EM. Echocardiographic assessment of left ventricular hypertrophy:comparison to necropsy findings. Am J Cardiol. 1986; 57:450-8.
34. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Deribis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251-60.
35. Hall JE, Brands MW, Henegar JR, Shek EW. Abnormal kidney function as a cause and a consequence of obesity hypertension. Clin Exp Pharm Phys. 1998; 25:58-64.
36. Kanai H, Tokunaga K, Fujloka S, Yamashita S, Kameda-Takemura KK, Matsuzawa Y. Decrease In intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertens. 1996; 27(1):125-9.
37. Wing RR, Jeffery RW, Burton LR, Thorson C, Kuller LH, Folsom AR. Change in waist-hip ratio with weight loss and its association with change in cardiovascular risk factors. Am J Clin Nutr. 1992; 55:1086-92.
38. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. ALLHAT Collaborative Research Group. J Clin Hypertens. 2002; 4:393-405.
39. Bakris GL. Maximizing cardiorenal benefit in the management of hypertension: achieve blood pressure goals. J Clin Hypertens. 1999; 1:141-7.
40. Modan M, Almog S, Fuchs Z, Chetrit A, Lusky A, Haskin H. Obesity, glucose intolerance, hyperinsulinemia and response to antihypertensive drugs. Hypertension. 1991; 17:565-73.
41. Zanella MT, Kohlmann Jr O, Ribeiro AB. Treatment of obesity hypertension and diabetes syndrome. Hypertension. 2001; 38:705-8.
42. Schmleder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy In essential hypertension: a meta-analysis of randomized double blind studies. JAMA. 1996; 275:1507-13.
43. Ruvolo G, Greco E, Speziale G, Di Natae M, Marino B. Effetti sulla massa ventricolare sinistra del tratamento comn amlodipina e dietoterapia in pazienti obesi affetti da ipertensione arteriosa. Minerva Cardioangiol. 1994; 42:289-92.
44. Barzizza F, Magnani L, Crea G, Richichi L. Regression of left ventricular hypertrophy in obese hypertensive patients treated with diet and pharmacologic therapy. G Ital Cardiol. 1992; 22:453-7.
45. Faria AN, Ribeiro Filho FF, Lerario DD, Kohlmann NE, Ferreira SR, Zanella MT, Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. Arq Bras Cardiol. 2002; 78:172-80.
46. Wirth A, Scholze J, Sharma AM, Matiba B, Boenner G. Reduced left ventricular mass after treatment of obese patients with sibutramine : An echocardiographic multicentre study. Diabetes Obes Metab. 2006; 8:674-81.
47. Schillaci G, Verdecchia P, de Simone G, Sacehi N, Bruni B, Benemio G et al. Persistance of increased left ventricular mass despite optimal blood pressure control in hypertens, Ital Heart J. 2000; 1:354-60,
48. Ribeiro Filho FF, Mariosa LS, Ferreira SR, Zanella MT. Visceral fat and metabolic syndrome: more than a simple association. Arq Bras Endocrinol Metabol. 2006; 50:230-8.
49. Mule G, Nardi E, Cottone S, Cusimano P, Incalterra F, Ester Giandalia M et al. Impact of metabolic syndrome on left ventricular mass in overweight and obese hypertensive subjects. Int J Cardiol. 2007; 26.
50. Bianchi S, Bigazzi R, Badari G, Campese VM. Microalbuminuria in patients with essential hypertension. Effects of several antihypertensive drugs. Am J Med. 1992; 93:525-8.
51. Praga M, Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens. 2006; 15:481-6.
52. Redon J. Antihypertensive treatment: should it be titrated to blood pressure reduction or to target organ damage regression? Curr Opin Nephrol Hypertens. 2005; 14:448-52.